Abstract submission
is now open for the next EACPT Congress, to be held in Geneva 28-31 August
2013. The congress includes symposia, keynote lectures and peer-reviewed oral
and poster communications
Symposium on Inflammatory
disease and biotherapeutics
The development of
biotherapeutics has considerably expanded during the last decade with the
formidable improvement of biotechnological tools and better validation of targets.
Inflammatory disorders represent indications of choice for the development of
biotherapeutics. An intense competition is taking place currently to find new
treatments for disorders against which the therapeutic armamentarium has
remained limited for a long time. This session will focus on the latest
therapeutic developments in the field of neurological and rheumatologic
inflammatory disorders and discuss the promise but also the limitations of
these new approaches.
2013
EACPT Congress
Over 900 participants are expected to attend including
health professionals, scientists, policy makers, biotechnology and pharmaceutical
professionals, and others with an interest
in basic and clinical pharmacology, pharmacotherapy,
drug discovery and development, regulatory affairs and related
areas.
See here for more on
key themes of the Congress.
EACPT Geneva 2013 Congress website www.eacpt2013.org
EACPT Geneva 2013 Congress website www.eacpt2013.org
Hi there! great stuff here, I'm glad that I drop by your page and found this very interesting. Thanks for posting about ocular inflammatory research. Hoping to read something like this in the future! Keep it up!
ReplyDeleteParticipating in a research study requires significant commitment on the participant’s behalf. Study visits may be lengthier, involve further testing not routinely prescribed, and require special concessions. For this, commercially-sponsored studies often offer compensation for time and trouble. Please consider this prior to evaluating whether or not you feel you or a loved one would be a viable candidate.